目的 探討注射用益氣復(fù)脈（凍干）對(duì)冠心病合并慢性心力衰竭患者的臨床療效。方法 回顧性選取三六三醫(yī)院2021年1月—2022年1月收治的冠心病合并慢性心力衰竭患者110例為研究對(duì)象。根據(jù)治療方案不同分為對(duì)照組和試驗(yàn)組，每組各55例。對(duì)照組患者采用常規(guī)治療方案，試驗(yàn)組在對(duì)照組基礎(chǔ)上加用注射用益氣復(fù)脈（凍干）治療：注射用益氣復(fù)脈（凍干）5.2 g加入5%葡萄糖注射液250 mL中靜脈滴注，每分鐘約40滴，每日1次，療程14 d。兩組均于治療2周后評(píng)估療效，分別于治療前后采用多普勒彩色超聲診斷儀檢測(cè)兩組患者左室收縮末期內(nèi)徑（LVESD）、左室舒張末期內(nèi)徑（LVEDD）、左室射血分?jǐn)?shù)（LVEF），以及血清末端腦鈉肽前體（NT-proBNP）、超敏C-反應(yīng)蛋白（hs-CRP）水平。結(jié)果 試驗(yàn)組臨床療效總有效率為92.73%，顯著高于對(duì)照組的83.64%，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后兩組患者LVEF均較本組治療前顯著提高（P<0.05），LVESD、LVEDD均較本組治療前顯著降低（P<0.05），治療后與對(duì)照組比較，試驗(yàn)組LVEF顯著提高（P<0.05），LVEDD顯著降低（P<0.05），LVESD差異無(wú)統(tǒng)計(jì)學(xué)意義（P>0.05）。治療后兩組患者血清NT-proBNP、hs-CRP水平均較本組治療前明顯降低（P<0.05），且治療后試驗(yàn)組與對(duì)照組比較，NT-proBNP、hs-CRP水平下降更顯著（P<0.05）。結(jié)論 在常規(guī)治療基礎(chǔ)上加用注射用益氣復(fù)脈（凍干）治療冠心病合并慢性心力衰竭患者，能明顯改善臨床癥狀及心功能，降低NT-proBNP和hs-CRP，提高臨床療效。

Objective To investigate the clinical effect of Yiqi Fumai Lyophilized Injection on patients with coronary atherosclerotic heart disease (CHD) and chronic heart failure. Methods A total of 110 patients with CHD and chronic heart failure admitted to the 363 Hospital from January 2021 to January 2022 were selected as the study objects. According to different treatment plans, they were divided into control group and experimental group, with 55 cases in each group. Patients in the control group were treated with conventional treatment scheme, while the patients in the experimental group were treated with Yiqi Fumai Lyophilized Injection on the basis of the control group:5.2 g of Yiqi Fumai Lyophilized Injection was added with 250 mL of 5% glucose injection for intravenous drip, about 40 drops per minute, once a day, and the course of treatment was 14 days. The efficacy of the two groups was evaluated after two weeks of treatment. Before and after treatment, the left ventricular end systolic diameter (LVESD), left ventricular end diastolic diameter (LVEDD), left ventricular ejection fraction (LVEF) were detected by Doppler color ultrasound diagnostic apparatus, as well as the level of serum N-terminal pro-brain natriuretic peptide (NT-proBNP) and hypersensitive Creactive protein (hs-CRP) were detected. Results The total effective rate of the experimental group was 92.73%, which was significantly higher than that of the control group (83.64%, P<0.05). After treatment, LVEF of patients in the two groups were significantly increased (P<0.05), LVESD and LVEDD were significantly decreased (P<0.05). Compared with the control group after treatment, LVEF in the experimental group was significantly increased (P<0.05), LVEDD was significantly decreased (P<0.05), and LVESD had no significant difference (P>0.05). After treatment, the levels of NT-proBNP and hs-CRP in the two group were significantly lower than those before treatment (P<0.05). After treatment, the levels of NT-proBNP and hs-CRP in the experimental group were significantly lower than those in the control group (P<0.05). Conclusion On the basis of routine treatment, Yiqi Fumai Lyophilized Injection can significantly improve clinical symptoms and cardiac function, reduce NT-proBNP and hs-CRP, and improve clinical efficacy in patients with CHD and chronic heart failure.

R972